Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:INGN NASDAQ:PDEX NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$10.00+0.3%$9.34$6.55▼$10.49$48.22M-0.133,497 shs596 shsINGNInogen$6.30-0.5%$6.70$5.70▼$13.33$170.20M1.72202,245 shs280,704 shsPDEXPro-Dex$45.73+1.4%$44.76$18.30▼$70.26$147.04M0.1947,900 shs24,268 shsSGHTSight Sciences$3.68+5.4%$3.84$2.03▼$7.05$180.42M2.44114,721 shs92,148 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+0.30%+1.01%+1.42%+29.87%+12.36%INGNInogen-0.47%-3.82%-13.22%-0.79%-22.70%PDEXPro-Dex+1.42%-9.05%-1.06%+5.42%+138.55%SGHTSight Sciences+5.44%+6.67%+6.05%+21.45%-32.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen4.009 of 5 stars3.33.00.03.91.41.71.3PDEXPro-Dex2.111 of 5 stars2.51.00.00.02.91.71.9SGHTSight Sciences1.4824 of 5 stars1.14.00.00.02.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00150.00% UpsideINGNInogen 2.50Moderate Buy$11.0074.60% UpsidePDEXPro-Dex 3.00Buy$56.0022.46% UpsideSGHTSight Sciences 2.29Hold$3.936.88% UpsideCurrent Analyst Ratings BreakdownLatest DXR, SGHT, INGN, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.006/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AINGNInogen$335.70M0.50N/AN/A$7.30 per share0.86PDEXPro-Dex$53.84M2.77$0.97 per share47.09$9.03 per share5.06SGHTSight Sciences$79.87M2.38N/AN/A$1.72 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AINGNInogen-$35.89M-$1.15N/AN/AN/A-8.08%-14.76%-9.01%8/7/2025 (Confirmed)PDEXPro-Dex$2.13M$2.8016.3322.20N/A14.61%29.08%16.19%9/4/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%8/7/2025 (Estimated)Latest DXR, SGHT, INGN, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q4 2025PDEXPro-Dex$0.47N/AN/AN/A$17.90 millionN/A8/7/2025Q2 2025INGNInogen-$0.25N/AN/AN/A$90.40 millionN/A8/7/2025Q2 2025SGHTSight Sciences-$0.25N/AN/AN/A$18.18 millionN/A5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AINGNInogenN/A3.072.67PDEXPro-Dex0.282.731.45SGHTSight Sciences0.5110.479.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%INGNInogen89.94%PDEXPro-Dex15.28%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%INGNInogen1.46%PDEXPro-Dex47.50%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableINGNInogen1,03026.89 million26.49 millionOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableSGHTSight Sciences21051.70 million35.72 millionOptionableDXR, SGHT, INGN, and PDEX HeadlinesRecent News About These CompaniesSight Sciences (SGHT) Projected to Post Earnings on ThursdayJuly 31, 2025 | marketbeat.comSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...July 30, 2025 | manilatimes.netMSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye DiseaseJuly 30, 2025 | globenewswire.comSight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye DiseaseJuly 29, 2025 | globenewswire.comSight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comSight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by BrokeragesJuly 19, 2025 | marketbeat.comWall Street Zen Downgrades Sight Sciences (NASDAQ:SGHT) to SellJuly 19, 2025 | marketbeat.com7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...July 15, 2025 | benzinga.comSight Sciences (NASDAQ:SGHT) Given New $4.00 Price Target at Morgan StanleyJuly 15, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 SharesJuly 8, 2025 | insidertrades.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells 4,889 Shares of StockJuly 7, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $23,681.43 in StockJuly 7, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $38,197.20 in StockJuly 7, 2025 | marketbeat.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells 23,637 Shares of StockJuly 7, 2025 | marketbeat.comSGHT - Sight Sciences Inc Chart - MorningstarJuly 5, 2025 | morningstar.comMSight Sciences Leads The Pack Of 3 Promising Penny StocksJune 24, 2025 | uk.finance.yahoo.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, SGHT, INGN, and PDEX Company DescriptionsDaxor NASDAQ:DXR$10.00 +0.03 (+0.30%) As of 08/6/2025 03:47 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Inogen NASDAQ:INGN$6.30 -0.03 (-0.47%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$6.20 -0.10 (-1.59%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Pro-Dex NASDAQ:PDEX$45.73 +0.64 (+1.42%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$45.57 -0.16 (-0.35%) As of 08/6/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Sight Sciences NASDAQ:SGHT$3.68 +0.19 (+5.44%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.68 0.00 (0.00%) As of 08/6/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
